Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Migration, Crosslink

📖

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-194-mitochondr

📖 Wiki Page

therapeutic1922 wordssynced 2026-04-02

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mdivi-1</td>
<td>Drp1 GTPase activity inhibitor[@wang2019]</td>
</tr>
<tr>
<td class="label">Dynasore</td>
<td>Drp1 GTPase inhibitor</td>
</tr>
<tr>
<td class="label">Drp1 siRNA/ASO[@bharathi2022]</td>
<td>Gene expression silencing</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Fis1 peptide inhibitors</td>
<td>Compete with Drp1 binding</td>
</tr>
<tr>
<td class="label">MFF modulators</td>
<td>Reduce Drp1 recruitment</td>
</tr>
<tr>
<td class="label">Fis1/MFF siRNA</td>
<td>Reduce expression</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Peptide blockers of tau-Drp1 binding[@insausti2023]</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Small molecule disruptors</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BZNP-1</td>
<td>MFN1/2</td>
</tr>
<tr>
<td class="label">A-9660853</td>
<td>OPA1</td>
</tr>
<tr>
<td class="label">NAC[@perez2018]</td>
<td>Global</td>
</t

...

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Mdivi-1</td>
<td>Drp1 GTPase activity inhibitor[@wang2019]</td>
</tr>
<tr>
<td class="label">Dynasore</td>
<td>Drp1 GTPase inhibitor</td>
</tr>
<tr>
<td class="label">Drp1 siRNA/ASO[@bharathi2022]</td>
<td>Gene expression silencing</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Fis1 peptide inhibitors</td>
<td>Compete with Drp1 binding</td>
</tr>
<tr>
<td class="label">MFF modulators</td>
<td>Reduce Drp1 recruitment</td>
</tr>
<tr>
<td class="label">Fis1/MFF siRNA</td>
<td>Reduce expression</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Peptide blockers of tau-Drp1 binding[@insausti2023]</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Small molecule disruptors</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BZNP-1</td>
<td>MFN1/2</td>
</tr>
<tr>
<td class="label">A-9660853</td>
<td>OPA1</td>
</tr>
<tr>
<td class="label">NAC[@perez2018]</td>
<td>Global</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1 activator</td>
</tr>
<tr>
<td class="label">SRT2104</td>
<td>SIRT1 selective</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>SIRT3 activity</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>SIRT1-mediated deacetylation</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>AMPK activation → PGC-1α phosphorylation</td>
</tr>
<tr>
<td class="label">AICAR</td>
<td>Direct AMPK activator</td>
</tr>
<tr>
<td class="label">SRT1720</td>
<td>SIRT1 activator</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>500-1000mg/day</td>
</tr>
<tr>
<td class="label">Berberine</td>
<td>500-1500mg/day</td>
</tr>
<tr>
<td class="label">AICAR</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">Liothyronine (T3)</td>
<td>Increases PGC-1α in models</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>Dual GLP-1/GIP increases PGC-1α</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Kaempferol</td>
<td>PINK1 stabilizer</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>Mitophagy inducer via TFEB</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR inhibition → TFEB activation</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>TFEB activator, autophagy enhancer</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Status</td>
</tr>
<tr>
<td class="label">UBX-L02</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">DHBE</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Compound 39</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BNIP3/NIX agonists</td>
<td>BNIP3</td>
</tr>
<tr>
<td class="label">FUNCYD1 modulators</td>
<td>FUNDC1</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Electron transport support</td>
</tr>
<tr>
<td class="label">L-carnitine</td>
<td>mtDNA polymerase cofactor</td>
</tr>
<tr>
<td class="label">α-lipoic acid</td>
<td>Mitochondrial cofactor</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">dGMP/dAMP precursors</td>
<td>Support mtDNA replication</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside (NR)</td>
<td>NAD+ precursor, supports POLG</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Protects mtDNA from oxidative damage</td>
</tr>
<tr>
<td class="label">SkQ1</td>
<td>Prevents mtDNA mutations</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>None significant</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>May enhance levodopa efficacy</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>CYP1A2 inhibitor may affect metabolism</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>May affect levodopa absorption</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>None significant</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>MAO inhibition additive?</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>Potential serotonin interaction</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Evidence Base</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Clinical Readiness</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Drug Interaction Risk</td>
<td>6/10</td>
</tr>
</table>

Mitochondrial dynamics—the balance between fission (division) and fusion (joining)—are fundamentally disrupted in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Tau pathology directly impairs mitochondrial function through multiple mechanisms: disrupting Drp1-mediated fission, reducing fusion protein expression, inhibiting PGC-1α-driven biogenesis, and compromising mitophagy clearance. This section covers advanced therapeutic strategies to restore mitochondrial dynamics, enhance biogenesis, promote mitophagy, and maintain mtDNA integrity in CBS/PSP.

Rationale for Therapy

Evidence in CBS/PSP

Drp1 Dysregulation: Post-mortem PSP brain tissue shows increased Drp1 expression and abnormal phosphorylation at Ser616, promoting excessive fission and mitochondrial fragmentation [bharathi2022]. In tauopathy models, tau binds to Drp1, altering its subcellular localization and activity.

Fusion Protein Deficiency: Expression of MFN1, MFN2, and OPA1 is significantly reduced in PSP substantia nigra, impairing mitochondrial fusion and leading to fragmented, dysfunctional mitochondria [insausti2023].

PGC-1α Downregulation: PGC-1α (PPARGC1A) expression is markedly reduced in PSP patient tissue, correlating with reduced mitochondrial mass and complex I deficiency [perez2018]. This compromises the cell's ability to generate new mitochondria.

Mitophagy Impairment: The PINK1/Parkin pathway is compromised in PSP, with decreased Parkin translocation to damaged mitochondria and reduced ubiquitination of mitochondrial outer membrane proteins [palikaras2018].

mtDNA Vulnerability: Elevated mtDNA deletions and reduced mtDNA copy number have been documented in PSP substantia nigra, contributing to impaired oxidative phosphorylation [jiang2020].

Therapeutic Opportunity

Restoring mitochondrial dynamics offers multiple benefits:

Improved neuronal energy status and ATP production
Reduced oxidative stress from fragmented mitochondria
Enhanced clearance of damaged mitochondria via mitophagy
Increased mitochondrial mass through biogenesis
Protection against tau-mediated mitochondrial toxicity

1. Mitochondrial Fission Modulation

1.1 Drp1 Inhibitors

Target: Dynamin-related protein 1 (Drp1) - the master regulator of mitochondrial fission

Therapeutic Rationale: Excessive Drp1 activity drives mitochondrial fragmentation in tauopathy. Inhibition restores fission/fusion balance.

Clinical Considerations: Drp1 inhibition must be carefully titrated - complete Drp1 blockade impairs mitochondrial quality control and can cause lethal phenotypes. Therapeutic window is narrow.

1.2 Fis1 and MFF Modulation

Target: Fis1 (mitochondrial fission 1 protein) and MFF (mitochondrial fission factor) - Drp1 adaptor proteins

Therapeutic Rationale: Fis1 and MFF recruit Drp1 to mitochondria. Their modulation provides upstream fission control.

1.3 Tau-Drp1 Interaction Blockers

Target: Pathological tau-Drp1 binding that recruits Drp1 to synapses

Therapeutic Rationale: Tau directly binds Drp1 at synapses, causing mislocalization and pathological fission.

2. Mitochondrial Fusion Enhancement

2.1 Fusion Protein Modulators

Target: MFN1, MFN2, OPA1 - the core fusion machinery

Therapeutic Rationale: Fusion proteins are downregulated in PSP. Enhancing their expression restores fusion capacity.

2.2 Sirtuin Modulation (SIRT1/3)

Target: SIRT1 (nuclear) and SIRT3 (mitochondrial) deacetylases

Mechanism: SIRT1 deacetylates PGC-1α, enhancing biogenesis. SIRT3 deacetylates MnSOD and IDH2, improving mitochondrial function. Both promote fusion indirectly.

3. PGC-1α Biogenesis Activation

3.1 Direct PGC-1α Activators

Target: PPARGGC1A gene and PGC-1α protein

Therapeutic Rationale: PGC-1α is the master regulator of mitochondrial biogenesis. Its activation increases mitochondrial mass and function.

3.2 AMPK Activation

Target: AMPK - the cellular energy sensor that drives biogenesis

Mechanism: AMPK phosphorylates PGC-1α directly and activates SIRT1 via NAD+ elevation.

3.3 Thyroid Hormone Analogues

Target: T3/T4 signaling via TRs

Mechanism: Thyroid hormone directly upregulates PGC-1α expression. T3 also increases mitochondrial density.

4. Mitophagy Enhancement

4.1 PINK1/Parkin Pathway Activation

Target: PINK1 kinase and Parkin E3 ligase

Therapeutic Rationale: The PINK1/Parkin pathway is the primary mitophagy trigger. Enhancing this pathway improves clearance of damaged mitochondria.

4.2 USP30 Inhibition

Target: USP30 - a deubiquitinase that removes ubiquitin from mitochondria, antagonizing Parkin

Therapeutic Rationale: USP30 inhibition enhances Parkin-mediated mitophagy by preserving ubiquitin tags [sklar2019].

Clinical Perspective: USP30 inhibitors are in early development for PD. May have applicability for CBS/PSP.

4.3 Alternative Mitophagy Pathways

Target: Receptor-mediated mitophagy (BNIP3, NIX, FUNDC1)

5. mtDNA Maintenance

5.1 mtDNA Replication Support

Target: mtDNA copy number and integrity

Therapeutic Rationale: mtDNA deletions accumulate with age and neurodegeneration. Supporting replication maintains functional mtDNA.

5.2 Nucleotide Supplementation

5.3 mtDNA Protection

6. Combined Mitochondrial Dynamics Protocol

Phase 1: Stabilization (Weeks 1-4)

Metformin: 500mg daily (titrate to 1000mg)
CoQ10: 300-600mg/day
Resveratrol: 250mg/day
NAC: 600mg/day

Phase 2: Enhancement (Weeks 5-12)

Continue Phase 1 agents
Add: Urolithin A (500mg/day) if available
Consider: AICAR (under supervision)
Monitor: mtDNA copy number, NfL

Phase 3: Maintenance (Ongoing)

Personalized maintenance based on biomarkers
Cycle on/off certain agents
Regular mitochondrial function assessment

7. Drug Interactions with Current Regimen

Levodopa Interactions

Rasagiline (MAO-B Inhibitor) Interactions

Key Contraindications

Avoid high-dose niacin with rasagiline (vasodilatory effects)
Avoid concurrent mitochondrial transplantation during active MAO-Bi treatment
Limit alcohol with high-dose CoQ10

8. NET Assessment for CBS/PSP Patient

NET Score: 38/60 (63.3%)

Priority Ranking: Tier 2 (behind anti-tau immunotherapy, GLP-1 agonists)

9. Patient-Specific Recommendations

Based on this patient's profile (male, 50s, CBS/PSP, on levodopa + rasagiline):

Start immediately (high priority):

Metformin 500mg daily (cardiovascular benefit, mitochondrial biogenesis)
CoQ10 300mg daily (mitochondrial support)
Continue NAC 600mg daily if already taking

Consider in 3-6 months:

Add Urolithin A (if available) for mitophagy enhancement
Add Resveratrol 250mg daily for SIRT1 activation

Monitor:

NfL (quarterly) - expect stabilization or modest decrease
mtDNA copy number in blood (baseline, 6 months)
Glucose and HbA1c (metformin effect)

Avoid:

High-dose AICAR (insufficient safety data)
USP30 inhibitors (not clinically available)
Drp1 inhibitors (narrow therapeutic window)

10. More Information

[Mitochondrial Dynamics Pathway](/mechanisms/mitochondrial-dynamics-pathway)
[Mitochondrial Biogenesis in Neurodegeneration](/therapeutics/mitochondrial-biogenesis-neurodegeneration)
[Mitochondrial Dysfunction in PSP](/mechanisms/psp-mitochondrial-dysfunction)
[Mitochondrial Quality Control](/cell-types/mitochondrial-quality-control)
[PGC-1α Signaling Pathway](/mechanisms/pgc1alpha-signaling-pathway)
[PINK1/Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-pathway)
[CoQ10 Therapy](/therapeutics/coq10-therapy)

11. References

[Youle RJ et al., Mitochondrial fission, fusion, and autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/30692599/)

[Wang Y et al., Drp1-mediated mitochondrial fission in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31412754/)

[Palikaras K et al., Mitophagy: pathways and molecular mechanisms (2018)](https://doi.org/10.1146/annurev-biochem-060815-014344)

[Perez CA et al., PGC-1α deficiency in PSP substantia nigra (2018)](https://pubmed.ncbi.nlm.nih.gov/30514392/)

[Sklar P et al., Inhibition of USP30 enhances PINK1/Parkin-mediated mitophagy (2019)](https://doi.org/10.1038/s41556-019-0428-9)

[Jiang H et al., Mitochondrial DNA mutations and pathogenesis in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32853906/)

[Insausti A et al., Tau pathology disrupts mitochondrial dynamics in human neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Bharathi et al., Hyperphosphorylated Drp1 mediates mitochondrial dysfunction in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

References

[Youle RJ et al., Mitochondrial Fission/Fusion, Mitochondrial fission, fusion, and autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/30692599/)

[Wang Y et al., Drp1 in Neurodegeneration, Drp1-mediated mitochondrial fission in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31412754/)

[Palikaras K et al., Mitophagy Pathways, Mitophagy: pathways and molecular mechanisms (2018)](https://doi.org/10.1146/annurev-biochem-060815-014344)

[Perez CA et al., PGC-1α in PSP, PGC-1α deficiency in PSP substantia nigra correlates with mitochondrial dysfunction (2018)](https://pubmed.ncbi.nlm.nih.gov/30514392/)

[Sklar P et al., USP30 and Mitophagy, Inhibition of USP30 enhances PINK1/Parkin-mediated mitophagy (2019)](https://doi.org/10.1038/s41556-019-0428-9)

[Jiang H et al., mtDNA in Neurodegeneration, Mitochondrial DNA mutations and pathogenesis in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32853906/)

[Insausti A et al., Mitochondrial Dynamics in Tauopathy, Tau pathology disrupts mitochondrial dynamics in human neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Bharathi et al., Drp1 Phosphorylation in PSP, Hyperphosphorylated Drp1 mediates mitochondrial dysfunction in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — 0.62 · Target: Cell-type-specific essential genes
[Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — 0.55 · Target: BDNF, CREB1, synaptic plasticity genes
[Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — 0.53 · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypothesis/h-e12109e3) — 0.67 · Target: MAP6
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria](/hypothesis/h-2a4e4ad2) — 0.57 · Target: BNIP3/BNIP3L

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-194-mitochondrial-dynamics-biogenesis-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-194-mitochondrial-dynamics-biogenesis-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ab5d45005529
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-194-mitochondrial-dynamics-biogenesis-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

384

Outgoing

441

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Overview

Section 194: Advanced Mitochondrial Dynamics and Biogenesis Therapy in CBS/PSP

Overview

Rationale for Therapy

Evidence in CBS/PSP

Therapeutic Opportunity

1. Mitochondrial Fission Modulation

1.1 Drp1 Inhibitors

1.2 Fis1 and MFF Modulation

1.3 Tau-Drp1 Interaction Blockers

2. Mitochondrial Fusion Enhancement

2.1 Fusion Protein Modulators

2.2 Sirtuin Modulation (SIRT1/3)

3. PGC-1α Biogenesis Activation

3.1 Direct PGC-1α Activators

3.2 AMPK Activation

3.3 Thyroid Hormone Analogues

4. Mitophagy Enhancement

4.1 PINK1/Parkin Pathway Activation

4.2 USP30 Inhibition

4.3 Alternative Mitophagy Pathways

5. mtDNA Maintenance

5.1 mtDNA Replication Support

5.2 Nucleotide Supplementation

5.3 mtDNA Protection

6. Combined Mitochondrial Dynamics Protocol

Phase 1: Stabilization (Weeks 1-4)

Phase 2: Enhancement (Weeks 5-12)

Phase 3: Maintenance (Ongoing)

7. Drug Interactions with Current Regimen

Levodopa Interactions

Rasagiline (MAO-B Inhibitor) Interactions

Key Contraindications

8. NET Assessment for CBS/PSP Patient

9. Patient-Specific Recommendations

10. More Information

11. References

References

Pathway Diagram

Related Hypotheses

💬 Discussion